Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 7c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q2 EPS of ($0.11), $0.07 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $9.65 million versus the consensus estimate of $9.39 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• SuperCom posts record Q2 revenue of $8.1M, EBITDA of $4M
• UBS Reiterates Buy Rating on Sysco (SYY) Following Trip to Company Headquarters